PDCD1 and melanoma: The FDA already approved specific monoclonal antibodies, known as ICIs, active against PD-1 (nivolumab), PD-L1 (pembrolizumab), and CTLA-4 (ipilimumab) for several types of tumor, such as melanoma, kidney, bladder and lung cancers, and Hodgkin lymphoma.